Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

By S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, David W. Johnson, R. Lalonde, A. Japour and 2 more. New England Journal of Medicine, 2002

692 citations recorded by the source corpus.

Subfields: Emergency Medicine, Infectious Diseases, Virology

View Paper: https://www.semanticscholar.org/paper/4bcd7ae9c581f496a8d672e52ef6dca91540e315

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Palmer
2. F. Maldarelli
3. A. Wiegand
4. G. Hanna
5. B. Bernstein
6. S. Brun
7. Heng Li
8. D. Kempf

Citations in the corpus

• Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. (2003, neutral): “navir (125 and 47 mg/dL, respectively) [32].”
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy (2008, methodology): “To further examine the biphasic nature of persistent viremia in patients on suppressive therapy, we conducted an analysis that included data from 157 patients in two studies who consistently had 50 copies of RNA per ml by conventional assays: the present study and a previous study (Abbott trial M98-”
• Coronavirus disease 2019 (COVID-19): current status and future perspectives (2020, background): “ficiency virus (HIV), leading to the production of immature, nonnfectious virus particles [68 , 69] .”